Project Grant R21DA060111
Award Date
8/15/24
Completion Date
7/31/26
Dollars Obligated
$406K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Miami, FL 33199, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $772,800 to the University of Florida to conduct research on pharmacologically targeting novel modulators of opioid signaling. The overarching goal is to dissociate the behavioral effects associated with opioid receptor activation to curb the development of dependence and tolerance. The research will involve using high-throughput screening...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop high-precision epigenetic therapeutics for treating opioid use disorder (OUD). The $398,137 award to Boston Interactome LLC, effective May 1, 2025 through April 30, 2026, will fund research to identify functional modulators of the G9A epigenetic protein complex that regulates DFosB expression under chronic opioid exposure. The goal...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $267,310 to the University of Miami to assess the functional role of calcitonin gene-related peptide (CGRP) expressing neurons within the parabrachial nucleus (CGRPPBN) in opioid reinforcement and to determine the associated gene expression and epigenetic changes. The goal is to explore non-opioid targets to treat opioid use disorder, a...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,876 to conduct preclinical trials targeting the neuropeptide S (NPS) receptor to mitigate opioid taking and seeking behaviors in animal models. The goals of the project are to demonstrate proof-of-concept that NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation in rats, which could inform the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,536 to Chemregen Inc.'s Human Biomolecular Research Institute in San Diego, CA. The funding supports research to design, synthesize, and test non-opioid drug candidates as potential treatments for opioid use disorder and fentanyl toxicity. Key objectives include characterizing the effects of opioids on human induced pluripotent stem...
This Project Grant award of $847,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to evaluate the therapeutic potential of neuropeptide S receptor 1 (NPSR1) agonism for reducing opioid self-administration and relapse in preclinical animal models. The research team at the University of Tennessee Health Science Center will leverage pharmacological tools to investigate NPSR1 as a novel target for treating...
This $265,302 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the neural mechanisms underlying opioid use disorder (OUD) and relapse risk during abstinence. The funded project will map the functional and anatomical pathways between the anterior and posterior paraventricular nucleus of the thalamus (PVT) and the nucleus accumbens (NAc), which have been implicated in the...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The grantee, Epivario Inc., a for-profit biotechnology research organization, will screen a new class of ACSS2 inhibitors and evaluate their efficacy in preclinical animal models of OUD. Specifically, the $275,253 award will support...
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $759,339 to The Trustees of the University of Pennsylvania to conduct research on the role of central amylin receptors in opioid-mediated behaviors. The key objectives are to: Comprehensively define the functional roles of cell type-specific ventral tegmental area (VTA) and nucleus accumbens (NAc) amylin receptors in opioid taking and seeking behaviors...